PDSB News and Press, PDS Biotechnology Corporation

Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...

2024-05-15 12:52:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips PDS Biotechnology (NASDAQ: PDSB ) just reported results for the first quarter of 2024. PDS Biotechnology reported earnings per share of -30 cents. This was above the analy...

2024-05-15 08:02:09 ET More on PDS Biotechnology PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade) Seeking Alpha’s Quant Rating on PDS Biotechnology Historical earnings data for PDS Biotechnology Financial in...

Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15,...

Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...

30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: P...

PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious...

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious...

PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious...

2024-05-02 08:25:25 ET More on PDS Biotechnology PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade) Read the full article on Seeking Alpha For further details see: PDS Biotechnology names Stephan Toutain as COO